Legal Settlements and Loss Contingencies	12 Months Ended
Dec. 31, 2021
Legal Settlements and Loss Contingencies	NOTE 11—Legal settlements and loss contingencies: Legal settlements and loss contingencies in 2021 were expenses of $717 million, compared to expenses of $60 million in 2020 and an expense of $1,178 million in 2019. The expenses in 2021 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, the provision for the carvedilol patent litigation as well as a liability which was substantially offset by insurance receivable related to the Ontario Teachers Securities Litigation discussed in note 12. The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). The expenses in 2019 were mainly related to an estimated provision recorded in connection with settlement of the remaining opioid cases. As of December 31, 2021 and 2020, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $2,710 million and $1,625 million, respectively. In connection with Teva’s provision for legal settlements and loss contingencies as of December 31, 2021 related to the Ontario Teachers Securities Litigation, Teva also recognized an insurance receivable as mentioned above.

Legal Settlements and Loss Contingencies

12 Months Ended

Dec. 31, 2021

Legal Settlements and Loss Contingencies

NOTE 11—Legal settlements and loss contingencies:

Legal settlements and loss contingencies in 2021 were expenses of $717 million, compared to expenses of $60 million in 2020 and an expense of $1,178 million in 2019. The expenses in 2021 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, the provision for the carvedilol patent litigation as well as a liability which was substantially offset by insurance receivable related to the Ontario Teachers Securities Litigation discussed in note 12.

The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics).

The expenses in 2019 were mainly related to an estimated provision recorded in connection with settlement of the remaining opioid cases.

As of December 31, 2021 and 2020, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $2,710 million and $1,625 million, respectively. In connection with Teva’s provision for legal settlements and loss contingencies as of December 31, 2021 related to the Ontario Teachers Securities Litigation, Teva also recognized an insurance receivable as mentioned above.